Astellas Pharma Inc.
4503
Xếp hạng trong cổ phiếu
#844
Astellas Pharma Inc., a venerable Japanese pharmaceutical enterprise... Astellas Pharma Inc., a venerable Japanese pharmaceutical enterprise established in 1923 and headquartered in Tokyo, operates globally in the research, development, manufacturing, and commercialization of a diverse range of medications. Its extensive product lineup addresses critical health needs, including various oncology treatments such as XTANDI for prostate cancer, XOSPATA, an FLT3 inhibitor for specific relapsed or refractory acute myeloid leukemia, and PADCEV for advanced urothelial cancer. For urological conditions, Astellas offers Betanis/Myrbetriq/BETMIGA to manage symptoms of overactive bladder, mirabegron for neurogenic detrusor overactivity in children, and Vesicare for OAB. Other notable pharmaceuticals include Eligard for prostate cancer, Harnal/Omnic for benign prostatic hyperplasia, Evrenzo for anemia associated with chronic kidney disease, and the immunosuppressants Prograf/Advagraf/Graceptor/ASTAGRAF, vital for preventing organ transplant rejection. The company also markets Funguard/MYCAMINE, an antifungal agent. Astellas actively fosters innovation through numerous strategic collaborations and partnerships. These include clinical trial agreements with pharmaceutical giants like Merck & Co., Inc. and CytomX Therapeutics, Inc. Demonstrating a broader approach to health, they collaborate with BANDAI NAMCO Entertainment Inc. on developing a smartphone exercise support application. In the realm of scientific discovery, Astellas maintains a research alliance with Harvard University for joint therapeutic and technological advancements. Further research initiatives involve Actinium Pharmaceuticals, Inc. to advance targeted radiotherapies leveraging their Antibody Warhead Enabling platform, an agreement with Zenith Epigenetics Ltd. to evaluate ZEN-3694, and a collaboration with Cytokinetics, Incorporated. A significant strategic alliance and license agreement exist with Minovia Therapeutics Ltd. to research, develop, and commercialize cell therapies for mitochondrial dysfunction.
Giá cổ phiếu
$15.81
Vốn hóa thị trường
$28.34B
Thay đổi (1 ngày)
0.26%
Thay đổi (1 năm)
47.95%
Quốc gia
JP
Giao dịch Astellas Pharma Inc. (4503)
Danh mục
Healthcare
Lịch sử giá cổ phiếu của Astellas Pharma Inc. (4503)
Giá đóng cửa cao nhất: $15.15 vào 2026-10-01
Giá đóng cửa thấp nhất: $5.02 vào 2001-12-01
Giá đóng cửa thấp nhất: $5.02 vào 2001-12-01
Lịch sử giá cổ phiếu của Astellas Pharma Inc. từ 2001 đến 2026
Hiệu suất giá cổ phiếu hàng năm
| Năm | Hiệu suất |
|---|---|
| 2026 (TTM) | 10.01% |
| 2025 | 30.86% |
| 2024 | -14.74% |
| 2023 | -23.52% |
| 2022 | -2.78% |
| 2021 | 8.47% |
| 2020 | -14.34% |
| 2019 | 21.97% |
| 2018 | 10.66% |
| 2017 | -7.13% |
| 2016 | -2.16% |
| 2015 | -1.95% |
| 2014 | 22.57% |
| 2013 | 20.47% |
| 2012 | 23.34% |
| 2011 | 5.95% |
| 2010 | -2.04% |
| 2009 | -4.93% |
| 2008 | -9.20% |
| 2007 | -1.72% |
| 2006 | 13.16% |
| 2005 | 6.13% |
| 2004 | 22.48% |
| 2003 | 10.77% |
| 2002 | 8.73% |
| 2001 | 0.00% |
Giá cổ phiếu của các công ty hoặc đối thủ tương tự
| Công ty | Giá cổ phiếu | Thay đổi 1năm% | Quốc gia |
|---|---|---|---|
| $1.31K | 61.56% |
US
|
|
| $266.13 | 37.93% |
US
|
|
| $283.82 | 24.11% |
US
|
|
| $151.83 | 73.30% |
US
|
|
| $482.01 | 30.76% |
CH
|
